comprehensive
Previous article：
BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Gilead might be held responsible for not developing a drug
Next article： Gilead might be held responsible for not developing a drug
leisure time
knowledge
-
Using force crossed my mind when examining a defiant young patient
2025-09-30 17:51
-
Gilead acquiring CymaBay and its liver disease drug for $4.3 billion
2025-09-30 17:09
-
Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more
2025-09-30 16:41
-
Using force crossed my mind when examining a defiant young patient
2025-09-30 16:18 -
To avoid data mishandling cases, universities eye AI and other tools
2025-09-30 15:59
-
Biogen Alzheimer’s drug launch off to slow start
2025-09-30 15:52